Måndag 11 November | 23:55:35 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

Tid*
2024-11-22 - X-dag ordinarie utdelning HAMLET B 0.00 SEK
2024-11-21 - Årsstämma
2024-11-15 09:00 Kvartalsrapport 2025-Q1
2024-08-28 - Bokslutskommuniké 2024
2024-05-24 - Kvartalsrapport 2024-Q3
2024-02-22 - Kvartalsrapport 2024-Q2
2023-12-14 - Extra Bolagsstämma 2024
2023-11-24 - X-dag ordinarie utdelning HAMLET B 0.00 SEK
2023-11-23 - Årsstämma
2023-11-17 - Kvartalsrapport 2024-Q1
2023-08-28 - Bokslutskommuniké 2023
2023-05-26 - Kvartalsrapport 2023-Q3
2023-05-17 - Extra Bolagsstämma 2023
2023-02-23 - Kvartalsrapport 2023-Q2
2022-11-25 - X-dag ordinarie utdelning HAMLET B 0.00 SEK
2022-11-24 - Årsstämma
2022-11-11 - Kvartalsrapport 2023-Q1
2022-08-26 - Bokslutskommuniké 2022
2022-05-20 - Kvartalsrapport 2022-Q3
2022-02-25 - Kvartalsrapport 2022-Q2
2021-11-26 - X-dag ordinarie utdelning HAMLET B 0.00 SEK
2021-11-25 - Årsstämma
2021-11-11 - Kvartalsrapport 2022-Q1
2021-08-27 - Bokslutskommuniké 2021
2021-06-17 - Extra Bolagsstämma 2022
2021-05-21 - Kvartalsrapport 2021-Q3
2021-03-02 - Extra Bolagsstämma 2021
2021-02-26 - Kvartalsrapport 2021-Q2
2020-11-27 - X-dag ordinarie utdelning HAMLET B 0.00 SEK
2020-11-26 - Årsstämma
2020-11-12 - Kvartalsrapport 2021-Q1
2020-08-28 - Bokslutskommuniké 2020
2020-05-22 - Kvartalsrapport 2020-Q3
2020-02-28 - Kvartalsrapport 2020-Q2
2019-11-22 - X-dag ordinarie utdelning HAMLET B 0.00 SEK
2019-11-21 - Årsstämma
2019-11-08 - Kvartalsrapport 2020-Q1
2019-08-30 - Bokslutskommuniké 2019
2019-05-17 - Kvartalsrapport 2019-Q3
2019-02-15 - Kvartalsrapport 2019-Q2
2018-11-16 - X-dag ordinarie utdelning HAMLET B 0.00 SEK
2018-11-15 - Årsstämma
2018-11-09 - Kvartalsrapport 2019-Q1
2018-08-30 - Bokslutskommuniké 2018
2018-05-18 - Kvartalsrapport 2018-Q3
2018-02-16 - Kvartalsrapport 2018-Q2
2017-11-10 - X-dag ordinarie utdelning HAMLET B 0.00 SEK
2017-11-09 - Årsstämma
2017-11-02 - Kvartalsrapport 2018-Q1
2017-08-18 - Bokslutskommuniké 2017
2017-05-12 - Kvartalsrapport 2017-Q3
2017-02-10 - Kvartalsrapport 2017-Q2
2017-01-19 - Extra Bolagsstämma 2018
2016-11-18 - Kvartalsrapport 2017-Q1
2016-11-11 - X-dag ordinarie utdelning HAMLET B 0.00 SEK
2016-11-10 - Årsstämma
2016-08-19 - Bokslutskommuniké 2016
2016-05-13 - Kvartalsrapport 2016-Q3
2016-02-12 - Kvartalsrapport 2016-Q2
2015-11-13 - Kvartalsrapport 2016-Q1

Beskrivning

LandSverige
ListaSpotlight
SektorHälsovård
IndustriBioteknik
Hamlet BioPharma är verksamt inom läkemedelsbranschen. Bolaget bedriver läkemedelsutveckling baserat på ett tumördödande protein-lipidkomplex, bildat av två naturliga och ofarliga molekyler som finns i bröstmjölk. Utvecklingen syftar till att ta fram preparat som primärt ska användas för behandling och prevention av cancersjukdomar. Studier görs idag på fall som berör blåscancer, och bolaget avser att utöka sin verksamhet till att omfatta andra cancerformer.
2024-09-11 13:26:30

Hamlet BioPharma, the pharmaceutical company, specializing in the development of drugs for cancer and infections, announces that Hamlet BioPharma's drug candidate Alpha1H has shown potent treatment effects on the majority of tumors in patients with cancer of the urinary bladder. The final analysis from placebo-controlled and dose-escalation studies is now published in Cancer Medicine, https://doi.org/10.1002/cam4.70149. The paper entitled `'Clinical and molecular response to alpha1-oleate treatment in patients with bladder cancer'' presents data on all study endpoints, confirming the therapeutic effects against tumors compared to placebo, with a lack of drug-related side effects observed in these patients.

Clinical effects of alpha1-oleate were quantified in patients with non-muscle invasive bladder cancer (NMIBC), using a randomized, placebo-controlled study protocol. Patients with NMIBC were treated by intra-vesical instillation of increasing concentrations of alpha1-oleate (Alpha1H) and the treatment response was defined relative to the placebo group.

Strong, dose-dependent anti-tumor effects were detected in Alpha1H treated patients for a combination of molecular and clinical indicators. A complete or partial response was observed in 88% of the tumors in the 8.5 mM group, compared to 47% of tumors treated with 1.7 mM of Alpha1H. The frequency of tumors with a complete response increased from 27% in the 1.7 mM to 44% in the 8.5 mM group. The average size reduction was 59% in the 8.5 mM group compared to 30% in the 1.7 mM group and 5% in the placebo group.

Treatment further triggered rapid tumor cell death by apoptosis, which is a beneficial mechanism of cell death with low toxicity. Alpha1H reached tumor tissue where it was taken up, as shown by the increased detection of Alpha1H in tumor biopsies from patients treated with the higher treatment dose. Intravesical Alpha1H administrations were followed by rapid, dose-dependent tumor cell shedding, resulting in increased cell numbers in the urine after each instillation, compared to each pre-instillation sample. The response was dose dependent, as defined by significantly higher cell numbers in patients receiving 8.5 mM compared to 1.7 mM of Alpha1H.

Alpha1H treatment further inhibited the expression of cancer gene networks, including bladder cancer genes. Tumor tissue that remained after treatment was changed in most patients, had lost tumor characteristics, and become more similar to healthy tissue. Drug-related side effects were not recorded, except for local irritation at the site of instillation.

These dose-dependent anti-tumor effects of Alpha1H are promising and support its potential in patients with NMIBC, initially as a neoadjuvant, targeting newly diagnosed tumors or recurrences. This potential has been acknowledged by the FDA (Food and Drug Administration, USA), which has awarded Alpha1H Fast Track status as a neoadjuvant for the treatment of bladder cancer.

For further information, please contact:

Catharina Svanborg, Chairman and Founder of Hamlet BioPharma, +46-709 42 65 49

catharina.svanborg@hamletpharma.com

Martin Erixon, CEO Hamlet BioPharma, +46-733 00 43 77

martin.erixon@hamletpharma.com

www.hamletbiopharma.com